Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

SECRETA
03 AUG 2

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required to Complete This Page**

1. Registrant Name

Watson Pharmaceuticals, Inc. (New Jersey)

2. Registrant Address ☐ Check if different than previously reported

Address **1101 17th Street N.W.** **Suite 500**

City **Washington** State/Zip (or Country) **DC 20036**

3. Principal Place of Business (if different from line 2)

City **Corona** State/Zip (or Country) **CA 92880**

4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
G. Thomas Long	**202-452-1102**	**gtlong@earthlink.net**	**63837-12**

7. Client Name ☒ Self — 6. House ID # **35518000**

TYPE OF REPORT

8. Year **2003** Midyear (January 1-June 30) ☒ **OR** Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____ 11. No Lobbyi

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000 ☐

$10,000 or more ☐ >> $ _____
Income (nearest $20,000)

Provide a good faith estimate, rounded to the nearest $20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this repo period were:

Less than $10,000 ☐

$10,000 or more ☒ >> $ **$240,000.00**
Expenses (nearest $20,(

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of o

☒ **Method A.** Reporting amounts using LDA definitio

☐ **Method B.** Reporting amounts under section 6033(the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e Internal Revenue Code

Signature _____ Date 08/14/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs Page

Registrant Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

Client Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **BUD** (one per page)

16. Specific Lobbying issues
HR 2673 S 1427, FY 2004 Agriculture Appropriations Bill, FDA Appropriations: OGD.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 08/14/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs Page

Registrant Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

Client Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **CPT** (one per page)

16. Specific Lobbying issues
HR 2491 , Greater Access to Affordable Pharmaceuticals Act,
S 54, Greater Access to Affordable Pharmaceuticals Act of 2003,
S1225, Greater Access to Affordable Pharmacueticals Act.,

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 08/14/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs Page

Registrant Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

Client Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **HCR** (one per page)

16. Specific Lobbying issues
Letters and visits to Members of Congress and Federal officials regarding Food and Drug Administration re activity covering issues and products of interest to the Registrant.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 08/14/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs Page

Registrant Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

Client Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **LBR** (one per page)
16. Specific Lobbying issues
S 946, Drug Competition Act of 2003,

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 08/14/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs Page

Registrant Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

Client Name: **Watson Pharmaceuticals, Inc. (New Jersey)**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **MMM** (one per page)

16. Specific Lobbying issues
HR 1, Medicare Prescription Drug and Modernization Act of 2003, Generic drug provisions and Medicare d reimbursement.
S 1, Prescription Drug and Medicare Improvement Act of 2003, Generic drug provisions and Medicare drug reimbursement.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 08/14/2003

Printed Name and Title G. Thomas Long - Vice President, Government Affairs Pag